Viking (VKTX) Q3 2026 Earnings Call Transcript
VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules.
VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules.
Even a small share of the massive market for weight loss drugs could lead to a significant increase in this company's share price.
The company continues to make good progress with its key obesity treatment drug, VK2735.
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
The biotech player could eventually rival big pharma companies.
The weight loss drug company continues to make progress, but its share price is bouncing around with events.
Record leasing activity and debt paydown fuel guidance hikes for Mexican industrial REIT.
The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.
Revenue grew 12% as newer products like CASGEVY and JOURNAVX ramped up significantly.
FILSPARI sales hit $200.2 million as FSGS launches alongside sustained IgAN demand.
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.